CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 85 enrolled
Drug / intervention
Interleukin-6 +3 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03170245
NCT03170245N/ACompleted
CompareCT.gov

Adiponectin, Interleukin-6 (IL-6) and High Sensitive C-reactive Protein (hsC-RP) in Relation to Carotid Intima-media Thickness in B-thalassemia Patients

Assiut University·observational·Posted May 31, 2017·Updated Feb 16, 2021

In Brief

An observational study evaluating Interleukin-6, HsC-RP, and 2 other interventions for Thalassemia. Completed, enrolled 85 participants across 1 site.

Detailed Summary

Every year, 100,000 neonates are born with hemoglobinopathies around the world. Thalassemia is the most common heterogeneous disease of the human being . It is a disease of high prevalence in Mediterranean, Indian, North Chinese, and Pacific populations. Recently, the quantity and quality of the life of these patients have been significantly improved by regular transfusion and iron chelating therapy .

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsThalassemia
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedMay 31, 2017
Enrollment StartAug 1, 2018
Primary CompletionJan 30, 2021
Study CompletionFeb 15, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.1 years ago

Interventions

Interleukin-6other

serum samples used for doing the test by ELISA

HsC-RPother

serum samples used for doing the test by ELISA

Adiponectin levelother

serum samples used for doing the test by ELISA

Carotid intima media thicknessother

Done by carotid doppler